Lonsurf with Bevacizumab for Metastatic Colorectal Cancer
Yes, Lonsurf (trifluridine/tipiracil) can and should be combined with bevacizumab for adults with metastatic colorectal cancer refractory to standard chemotherapy, as this combination significantly improves survival compared to Lonsurf alone.
FDA-Approved Indication and Dosing
The FDA has approved Lonsurf in combination with bevacizumab specifically for metastatic colorectal cancer patients previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy 1.
Recommended Dosing Regimen
Standard dosing: 35 mg/m² (based on trifluridine component) orally twice daily with food on Days 1-5 and Days 8-12 of each 28-day cycle, combined with bevacizumab per its prescribing information 1.
- Round dose to nearest 5 mg increment
- Maximum 80 mg per dose
- Continue until disease progression or unacceptable toxicity
- Swallow tablets whole; do not retake vomited or missed doses
For severe renal impairment (CrCl 15-29 mL/min): Reduce to 20 mg/m² twice daily 1.
Evidence Supporting the Combination
The phase III SUNLIGHT trial provides the strongest evidence for this combination 2. In 492 patients with refractory metastatic colorectal cancer:
- Median overall survival: 10.8 months (combination) vs 7.5 months (Lonsurf alone); HR 0.61, P<0.001
- Median progression-free survival: 5.6 months vs 2.4 months; HR 0.44, P<0.001
- Time to performance status worsening: 9.3 months vs 6.3 months; HR 0.54
This represents a 39% reduction in mortality risk with the addition of bevacizumab 2.
The 2024 NCCN guidelines explicitly list trifluridine-tipiracil with bevacizumab as preferred over trifluridine-tipiracil alone based on these data 3.
Treatment Sequencing
This combination can be given before or after regorafenib or fruquintinib - no data definitively establish optimal sequencing 4, 3. However:
- Real-world data show better patient adherence to trifluridine-tipiracil compared to regorafenib 4, 3
- The 144 RECOURSE trial patients with prior regorafenib exposure obtained similar benefit from trifluridine-tipiracil (HR 0.69) as those without prior regorafenib 4
Safety Profile and Monitoring
Most Common Adverse Events (≥20% in SUNLIGHT)
- Neutropenia (most common grade ≥3 event)
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
- Increased liver enzymes (AST, ALT, alkaline phosphatase)
- Decreased sodium
- Diarrhea
- Abdominal pain
- Decreased appetite
Critical Monitoring Requirements
Obtain complete blood counts:
- Prior to each cycle
- On Day 15 of each cycle 1
Withhold treatment if:
- ANC <500/mm³ or febrile neutropenia
- Platelets <50,000/mm³
- Grade 3-4 non-hematologic adverse reactions
Resume at reduced dose (5 mg/m²/dose reduction) after recovery if:
- Febrile neutropenia occurs
- Uncomplicated grade 4 neutropenia/thrombocytopenia causes >1 week cycle delay
- Grade 3-4 non-hematologic toxicity (except controlled nausea/vomiting or responsive diarrhea)
Maximum 3 dose reductions permitted; permanently discontinue if unable to tolerate 20 mg/m² twice daily 1.
Bevacizumab-Specific Precautions
- Increased risk of arterial thrombotic events, especially in patients ≥65 years 5, 6
- Monitor for hypertension, proteinuria, bleeding, gastrointestinal perforation
- May interfere with wound healing 7, 4
Special Populations
Elderly patients (≥65 years): Grade 3-4 neutropenia and thrombocytopenia occur more commonly 1. However, pooled safety analyses show the combination remains manageable with appropriate monitoring 8.
Vulnerable patients: Real-world data from the TWILIGHT study demonstrate acceptable efficacy and safety in patients intolerant of intensive therapy, with median OS of 18.6 months and PFS of 6.3 months 9.
Do NOT initiate in patients with baseline moderate or severe hepatic impairment 1.
Common Pitfalls to Avoid
Do not use trifluridine-tipiracil as first-line therapy - despite phase III data showing non-inferiority to capecitabine plus bevacizumab (SOLSTICE, TASCO1 trials), concerns about hematologic and financial toxicity preclude first-line use 3, 10
Do not combine anti-VEGF with anti-EGFR antibodies - this is explicitly not recommended 7, 4, 11
Do not use capecitabine-based regimens after progression on fluoropyrimidine-containing therapy - shown to be ineffective 7
Ensure proper patient selection - patients must have received prior fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF therapy, and if RAS wild-type, anti-EGFR therapy 1
Quality of Life Considerations
SUNLIGHT trial QoL analyses showed no clinically relevant deterioration in quality of life with the combination, and patients maintained better performance status longer compared to Lonsurf alone 12. This is clinically meaningful in the refractory setting where maintaining functional status is paramount.